The Survival of Patients with Inoperable Lung Cancer: A Large-Scale Randomized Study of Radiation Therapy Versus Placebo

Radiology ◽  
1968 ◽  
Vol 90 (4) ◽  
pp. 688-697 ◽  
Author(s):  
Bernard Roswit ◽  
Mary Ellen Patno ◽  
Robert Rapp ◽  
Arnolds Veinbergs ◽  
Bernard Feder ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Large Scale ◽  
Randomized Study

Split-Dose Intensive Radiation Therapy in the Treatment of Advanced Lung Cancer: A Randomized Study

Radiology ◽  
1967 ◽  
Vol 88 (6) ◽  
pp. 1159-1169 ◽  
Author(s):  
Seymour H. Levitt ◽  
C. R. Bogardus ◽  
George Ladd
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Randomized Study ◽  
Advanced Lung Cancer ◽  
Split Dose

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.

1997 ◽  
Vol 15 (3) ◽  
pp. 893-900 ◽  
Author(s):  
B Jeremic ◽  
Y Shibamoto ◽  
L Acimovic ◽  
S Milisavljevic
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Randomized Study ◽  
Survival Rates ◽  
Concurrent Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Group I ◽  
Hyperfractionated Radiation Therapy ◽  
Group Ii

PURPOSE To perform a randomized study of the optimal timing of thoracic radiation (RT) as accelerated hyperfractionated radiation therapy (ACC HFX RT) in combination with concurrent chemotherapy (CHT) in limited-stage small-cell lung cancer (SCLC). PATIENTS AND METHODS Between 1988 and 1992, 107 patients were enrolled and 103 were assessable. All patients received ACC HFX RT with 1.5 Gy twice daily to 54 Gy plus concurrent daily carboplatin/etoposide (C/E) (30 mg each) and four sequential cycles of cisplatin/etoposide (PE) (30 mg/m2 and 120 mg/m2, respectively, on days 1 to 3). Group I patients (n = 52) received concurrent chemoradiation at weeks 1 to 4, and group II (n = 51) at weeks 6 to 9. Patients who showed a complete response (CR) or partial response (PR) underwent prophylactic cranial irradiation (PCI) at weeks 16 to 17. RESULTS The median survival time was 34 months in group I and 26 months in group II, and the Kaplan-Meier 5-year survival rates were 30% and 15%, respectively. The difference was almost significant on univariate analysis (P = .052) and was significant on multivariate analysis (P = .027). Group I patients had a significantly higher local control rate than group II patients, but there was no difference between the two groups in distant metastasis rate. There was no difference in the incidence of acute or late grade 3 to 4 toxicity. CONCLUSION Initial administration of thoracic ACC HFX RT with concurrent C/E seems to produce better local control and survival rates than delayed administration.

Sign in / Sign up

Export Citation Format

Share Document